These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 26540031)
1. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment. Zu M; Li C; Fang JS; Lian WW; Liu AL; Zheng LS; Du GH Molecules; 2015 Nov; 20(11):19735-47. PubMed ID: 26540031 [TBL] [Abstract][Full Text] [Related]
2. Regulation of influenza A virus mRNA splicing by CLK1. Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694 [TBL] [Abstract][Full Text] [Related]
3. Expression, purification and crystallization of CLK1 kinase - A potential target for antiviral therapy. Dekel N; Eisenberg-Domovich Y; Karlas A; Meyer TF; Bracher F; Lebendiker M; Danieli T; Livnah O Protein Expr Purif; 2020 Dec; 176():105742. PubMed ID: 32866611 [TBL] [Abstract][Full Text] [Related]
4. Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth. Li C; Xu LJ; Lian WW; Pang XC; Jia H; Liu AL; Du GH Acta Pharmacol Sin; 2018 Dec; 39(12):1913-1922. PubMed ID: 29802302 [TBL] [Abstract][Full Text] [Related]
5. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585 [TBL] [Abstract][Full Text] [Related]
6. Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs. An L; Liu R; Tang W; Wu JG; Chen X Antiviral Res; 2014 Sep; 109():54-63. PubMed ID: 24971493 [TBL] [Abstract][Full Text] [Related]
7. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399 [TBL] [Abstract][Full Text] [Related]
8. Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors. Saldivia M; Fang E; Ma X; Myburgh E; Carnielli JBT; Bower-Lepts C; Brown E; Ritchie R; Lakshminarayana SB; Chen YL; Patra D; Ornelas E; Koh HXY; Williams SL; Supek F; Paape D; McCulloch R; Kaiser M; Barrett MP; Jiricek J; Diagana TT; Mottram JC; Rao SPS Nat Microbiol; 2020 Oct; 5(10):1207-1216. PubMed ID: 32661312 [TBL] [Abstract][Full Text] [Related]
9. A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. Martinez-Gil L; Alamares-Sapuay JG; Ramana Reddy MV; Goff PH; Premkumar Reddy E; Palese P Antiviral Res; 2013 Oct; 100(1):29-37. PubMed ID: 23891991 [TBL] [Abstract][Full Text] [Related]
10. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Eichelberger MC; Hassantoufighi A; Wu M; Li M Virol J; 2008 Sep; 5():109. PubMed ID: 18822145 [TBL] [Abstract][Full Text] [Related]
11. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419 [TBL] [Abstract][Full Text] [Related]
12. Identification of Polo-like kinases as potential novel drug targets for influenza A virus. Pohl MO; von Recum-Knepper J; Rodriguez-Frandsen A; Lanz C; Yángüez E; Soonthornvacharin S; Wolff T; Chanda SK; Stertz S Sci Rep; 2017 Aug; 7(1):8629. PubMed ID: 28819179 [TBL] [Abstract][Full Text] [Related]
13. Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening. Walter A; Chaikuad A; Loaëc N; Preu L; Knapp S; Meijer L; Kunick C; Koch O Mol Inform; 2017 Apr; 36(4):. PubMed ID: 28000414 [TBL] [Abstract][Full Text] [Related]
14. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency. ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683 [TBL] [Abstract][Full Text] [Related]
15. Screening methods for influenza antiviral drug discovery. Atkins C; Evans CW; White EL; Noah JW Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452 [TBL] [Abstract][Full Text] [Related]
16. Recent discoveries of influenza A drug target sites to combat virus replication. Patel H; Kukol A Biochem Soc Trans; 2016 Jun; 44(3):932-6. PubMed ID: 27284062 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo assay systems for study of influenza virus inhibitors. Sidwell RW; Smee DF Antiviral Res; 2000 Oct; 48(1):1-16. PubMed ID: 11080536 [TBL] [Abstract][Full Text] [Related]
19. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Ozawa M; Shimojima M; Goto H; Watanabe S; Hatta Y; Kiso M; Furuta Y; Horimoto T; Peters NR; Hoffmann FM; Kawaoka Y Sci Rep; 2013; 3():1106. PubMed ID: 23346363 [TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis. Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]